Filing Flows › Comparisons › NAMS vs SEPN
NewAmsterdam Pharma Co N.V. vs Septerna: NAMS and SEPN compared
NewAmsterdam Pharma Co N.V. is the larger company: $19.2M of revenue in its latest quarter (Q3 2026) against $18.9M for Septerna (Q3 2026). NewAmsterdam Pharma Co N.V. is growing faster (55× against -12% a year earlier). Septerna is more profitable, with an operating margin of -144.2% against -230.6%.
Where the money goes: NAMS and SEPN
NewAmsterdam Pharma Co N.V. (NAMS) · Q3 2026
NewAmsterdam Pharma Co N.V., Q3 2026: revenue $19.2M (55× year over year), operating margin -230.6%, net loss $17.4M, operating cash flow −$39.8M. The chart follows the revenue to costs, profit and cash.
Septerna (SEPN) · Q3 2026
Septerna, Q3 2026: revenue $18.9M (-12% year over year), operating margin -144.2%, net loss $26.6M, operating cash flow −$13.8M. The chart follows the revenue to costs, profit and cash.
| NewAmsterdam Pharma Co N.V. (NAMS) | Septerna (SEPN) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $19.2M | $18.9M |
| Revenue growth, Y/Y | 55× | -12% |
| Operating margin | -230.6% | -144.2% |
| Net earnings | −$17.4M | −$26.6M |
| Net margin | -90.7% | -140.8% |
| Operating cash flow | −$39.8M | −$13.8M |
Questions
Which is bigger, NewAmsterdam Pharma Co N.V. or Septerna?
NewAmsterdam Pharma Co N.V. is the larger company: $19.2M of revenue in its latest quarter (Q3 2026) against $18.9M for Septerna (Q3 2026).
Is NewAmsterdam Pharma Co N.V. or Septerna growing faster?
NewAmsterdam Pharma Co N.V. is growing faster (55× against -12% a year earlier).
Which is more profitable, NewAmsterdam Pharma Co N.V. or Septerna?
Septerna is more profitable, with an operating margin of -144.2% against -230.6%.
More: NewAmsterdam Pharma Co N.V. earnings · how NewAmsterdam Pharma Co N.V. makes money · Septerna earnings · how Septerna makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.